Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Total Non-Current Liabilities data on record, last reported at $414000.0 in Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities fell 22.03% year-over-year to $414000.0; the TTM value through Jun 2025 reached $414000.0, down 22.03%, while the annual FY2024 figure was $593000.0, 8.49% down from the prior year.
  • Total Non-Current Liabilities reached $414000.0 in Q2 2025 per CRVS's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $6.3 million in Q1 2025 and bottomed at $414000.0 in Q2 2025.
  • Average Total Non-Current Liabilities over 4 years is $1.2 million, with a median of $686000.0 recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 34.21% in 2023, then soared 961.01% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $985000.0 in 2022, then crashed by 34.21% to $648000.0 in 2023, then dropped by 8.49% to $593000.0 in 2024, then tumbled by 30.19% to $414000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $414000.0 in Q2 2025, $6.3 million in Q1 2025, and $593000.0 in Q4 2024.